InfuSystem (INFU) investor relations material

Executive summary

• Achieved record quarterly revenue of $36.9 million in Q2 2026, up 2.6% year-over-year, driven by strong Patient Services growth and a decline in Device Solutions revenue.

• Oncology revenue surpassed $20 million for the first time, growing 6.4% year-over-year, while wound care revenue increased 154%, led by compression devices for lymphedema.

• Net income rose to $3.2 million ($0.15–$0.16 per diluted share), up from $2.6 million ($0.12 per share) in Q2 2025.

• Adjusted EBITDA increased 7.6% to $8.6 million, with margin expanding to 23.4%.

• Restructuring of the GE HealthCare contract reduced Device Solutions revenue but improved profitability and margins.

Financial highlights

• Gross profit for Q2 2026 rose 7.7% to $21.4 million, with gross margin improving to 58% from 55.2%.

• Patient Services revenue grew 15.2% to $24.8 million, while Device Solutions revenue declined 16.1% to $12.1 million.

• Operating income for Q2 2026 was $4.2 million, up from $3.8 million in Q2 2025.

• Operating cash flow for the first half of 2026 was $7.7 million, down year-over-year due to higher working capital needs.

• Stock repurchases totaled $4.4 million in H1 2026; liquidity stood at $55.2 million as of June 30, 2026.

Outlook and guidance

• Full-year 2026 net revenue guidance reaffirmed, with pro-forma growth expected between 6% and 8%.

• Adjusted EBITDA margin anticipated to remain in the low to mid 20% range, targeting 22%–25% long-term.

• Oncology and wound care growth trends expected to continue through 2026 and beyond.

• Ongoing investments in IT and ERP system upgrades are anticipated to support operational efficiency.

• Management expects continued profitable growth and efficiency improvements.